• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines

tetano

Editor, Senior Moderator
J Infect Public Health


. 2024 Mar 1;17(4):704-711.
doi: 10.1016/j.jiph.2024.02.016. Online ahead of print. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines

Fayhan Alroqi[SUP] 1 [/SUP], Tlili Barhoumi[SUP] 2 [/SUP], Emad Masuadi[SUP] 3 [/SUP], Maysa Nogoud[SUP] 2 [/SUP], Modhi Aljedaie[SUP] 2 [/SUP], Ahmad Selah Abu-Jaffal[SUP] 4 [/SUP], Maha Bokhamseen[SUP] 2 [/SUP], Myaad Saud[SUP] 5 [/SUP], Maumonah Hakami[SUP] 2 [/SUP], Yaseen M Arabi[SUP] 6 [/SUP], Amre Nasr[SUP] 7 [/SUP]



Affiliations
Abstract

Background: The global challenge posed by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been a major concern for the healthcare sector in recent years. Healthcare workers have a relatively high risk of encountering COVID-19 patients, making protective immunity against SARS-CoV-2 is a priority for them. This study aims to evaluate the longitudinal measurement of SARS-CoV-2 IgG spike protein antibodies in healthcare workers (HCWs) after COVID-19 infection and after receiving the first and second doses of SARS-CoV-2 vaccines, including Pfizer-BioNTech (BNT162b2) and Oxford-AstraZeneca (AZD1222).
Methods: This longitudinal cohort study involved 311 healthcare workers working in two tertiary hospitals in Saudi Arabia. All participants were followed between July 2020 and July 2022 after completing the study questionnaire. A total of 3 ml of the blood samples were collected at four intervals: before/after vaccination.
Results: HCWs post-infection had lower mean SARS-CoV-2 IgG levels three months post-infection than post-vaccination. 92.2% had positive IgG levels two weeks after the first dose and reached 100% after the second dose. Over 98% had positive antibodies nine months after the second dose, regardless of vaccine type. The number of neutralizing antibodies decreased and was around 50% at nine months after the second dose.
Conclusion: The results show different antibody patterns between infected and vaccinated HCWs. A high proportion of participants had positive antibodies after vaccination, with high levels persisting nine months after the second dose. Neutralizing antibodies decreased over time, with only about 50% of participants having positive antibodies nine months after the second dose. These results contribute to our understanding of immunity in healthcare workers and highlight the need for the continuous monitoring and possible booster strategies.

Keywords: COVID-19, vaccine, IgG antibody, KSA; Healthcare workers; SARS-CoV-2.

 
Back
Top Bottom